Filter by financial year:
| Date | Particulars | |
|---|---|---|
| 17 February, 2026 | Completion of acquisition of Neviton Softech Private Limited |
|
| 05 February, 2026 | Strides Pharma Inc receives USFDA closure report (EIR) for its formulations facility at Chestnut Ridge, New York Inspection included Drug Device Combinations covering our recent filing in Nasal Sprays domain |
|
| 30 January, 2026 | Audio Recording of Earnings Call pertaining to the Unaudited Financial Results for the quarter and nine months ended December 31, 2025 |
|
| 24 December, 2025 | Completion of US-FDA Inspection at the Formulations Facility of Strides Pharma Inc., USA, a step-down wholly owned subsidiary of the Company |
|
| 22 December, 2025 | Intimation of closure of trading window – Q3FY26 |
|
| 03 December, 2025 | Movement in Senior Management Personnel |
|
| 17 October, 2025 | Strides and Incepta Partner to Expand Women’s Health Access with WHO-Prequalified Contraceptive |
|
| 25 September, 2025 | Intimation of closure of trading window - Q2FY26 |
|
| 24 September, 2025 | Sustainability Report FY25 |
|
| 08 September, 2025 | Strides Enters into a Strategic Product Development Partnership with Kenox to Expand Nasal Spray Portfolio for the US Market |
|
